Allogene Therapeutics, Inc. (ALLO)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 1
Do Nothing: fundamentalScore is 2 (below the required floor of 3), which hard-blocks any long entry, and the chart independently offers no qualifying long — a pullback/oversold limit would be a countertrend bid (price 0.8387 below SMA50 1.41 with MACD line -0.15) while the breakout-stop alternative has no base at a 52-week low.
Company overview
Allogene Therapeutics, Inc. is a clinical-stage company focused on developing genetically engineered allogeneic T-cell therapies for cancer treatment. Its key products include UCART19 for B-cell acute lymphoblastic leukemia and ALLO-501 for non-Hodgkin lymphoma. The company collaborates with several partners, including Pfizer and MD Anderson Cancer Center.
Fundamental
weakAllogene's fundamentals are weak, characterized by negative cash flow and heavy dilution, offset by a strong liquidity position.
Pre-revenue clinical-stage allogeneic CAR-T developer with no product revenue and large operating losses (negative ROE/ROIC and deeply negative free cash flow), offset by $388.9 million of cash and investments, no debt facilities, no going-concern warning and a runway into Q1 2029. Heavy 2026 dilution (~51% share-count growth with $135 million of ATM capacity still open), a binary ALPHA3 clinical path, management turnover and negative DCF values produce an elevated-risk, weak-fundamentals profile in which the liquidity cushion is the principal mitigant.
Sentiment
fairSentiment is mixed, with recent positive clinical data not yet impacting the stock price.
The dominant near-term driver is the first ALLO-329 Phase 1 RESOLUTION autoimmune dataset (announced, 2026-11-09), scored net-positive in both the first-party analyzer (+0.6) and third-party coverage (+0.5), set against a determinate improving sentiment delta (baseline polarity +0.035 → scoring polarity +0.267) and a Red-Flag Screen clean of both severe and moderate flags, so no red-flag cap applies. The setup nonetheless stays in the mixed/forming band because the anchoring catalyst is trailing and only partially priced with no forward-dated driver inside 30 days, and the equity tape has not confirmed the constructive press — the $0.8387 quote sits at the bottom of its $0.82–$4.46 52-week range.
Technical
very weakThe stock is in a confirmed downtrend, trading at the low end of its range with no base for a breakout.
Chart quality 1/5: broken, high-conviction downtrend. Price 0.8387 sits below SMA20 (1.14), SMA50 (1.41), SMA200 (1.95), EMA9 (0.97), EMA21 (1.12), WMA9 (0.94), WMA21 (1.06), DEMA14 (0.88) and the 2026-11-13 daily VWAP (0.8408); only TEMA14 (0.85) is beneath spot. ADX14 at 46.04 and rising while price trades under the entire moving-average stack is trend strength pointing DOWN, not up. MACD is negative and expanding (-0.15 line vs -0.13 signal, histogram -0.02) on every one of the last four sessions. RSI14 23.48 and Williams %R -96.68 are deeply oversold, but oversold inside a waterfall is not a base — price is printing lower lows into the 52-week floor (0.82), tagged intraday on both 11-12 and 11-13. The tape is a failed-catalyst tape: the 2026-11-09 ALLO-329 Phase 1 release closed at 1.06 and the stock has been sold every session since (0.9319 → 0.9001 → 0.827), roughly -21% in four sessions on heavy distribution volume (22.9M shares on 11-10). ATR14 0.10 is 11.9% of price — the name has plenty of range, it is just using it to the downside. No constructive long structure exists: a pullback/oversold limit would be a countertrend bid (price < SMA50 with MACD < 0, and price < a declining SMA200 with no momentum reclaim), and a buy-stop breakout has no base — every settled overhead level (11-12 high 0.8969, 11-11 high 0.96) sits inside the falling EMA9/EMA21 stack, so structural risk would have to sit beneath the 0.82 low against ~2.0×ATR of reward. Layered on top, fundamentalScore is 2 (< 3), which is a hard block on any long entry regardless of the chart.
You’re looking at 2026-11-14 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

